英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
turkois查看　turkois　在百度字典中的解释百度英翻中〔查看〕
turkois查看　turkois　在Google字典中的解释Google英翻中〔查看〕
turkois查看　turkois　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • IDHIFA®: For Relapsed Refractory Acute Myeloid Leukemia | Patient Site
    WHAT IS IDHIFA ® (enasidenib)? IDHIFA ® is a prescription medicine used to treat people with acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation whose disease has come back or has not improved after previous treatment (s) It is not known if IDHIFA is safe and effective in children
  • Enasidenib Uses, Side Effects Warnings - Drugs. com
    Enasidenib is used to treat acute myeloid leukemia (AML) in adults with an IDH2 mutation enasidenib is used when AML has come back or has not improved with prior treatment Enasidenib may also be used for purposes not listed in this medication guide
  • Enasidenib Tablets: Uses Side Effects - Cleveland Clinic
    Enasidenib is a medication that works to stop cancer cells from growing It treats acute myelogenous leukemia This is a blood and bone marrow cancer that spreads quickly This medication comes in a tablet form that you can take by mouth with a glass of water as directed What is this medication?
  • FDA Approves Enasidenib (Idhifa), a First-of-Its-Kind Drug, for . . .
    Enasidenib (previously known as AG-221) belongs to an emerging class of epigenetic drugs These medications work to correct patterns of misdirected gene activity stemming from the way DNA is packaged in cells
  • FDA approves new targeted treatment for relapsed or refractory acute . . .
    The U S Food and Drug Administration today approved Idhifa (enasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific
  • Enasidenib: Side Effects, Uses, Dosage, Interactions, Warnings - RxList
    Enasidenib is a prescription medication used for the treatment of relapsed refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 mutation as detected by an FDA-approved test
  • Enasidenib: Uses, Interactions, Mechanism of Action - DrugBank Online
    This small molecule acts as an allosteric inhibitor of mutant IDH2 enzyme to prevent cell growth, and it also has shown to block several other enzymes that play a role in abnormal cell differentiation First developed by Agios Pharmaceuticals and licensed to Celgene, enasidenib was approved by U S Food and Drug Administration on August 1, 2017
  • Enasidenib: MedlinePlus Drug Information
    Enasidenib is used to treat a certain type of acute myeloid leukemia (AML; a type of cancer that begins in the white blood cells) that has worsened or come back after treatment with other chemotherapy medications Enasidenib is in a class of medications called an isocitrate dehydrongenase-2 (IDH2) inhibitor
  • Enasidenib: First Global Approval - PubMed
    Enasidenib has been approved in the USA for the treatment of adults with relapsed or refractory acute myeloid leukaemia (AML) and an IDH2 mutation as detected by an FDA-approved test It is at various stages of development in other countries for AML, myelodysplastic syndromes and solid tumours
  • Enasidenib - Indications, Dosage, Side Effects and Precautions
    Enasidenib is an isocitrate dehydrogenase 2 inhibitor It is prescribed to treat acute myeloid leukemia in adult patients who have not responded to treatment or relapsed following





中文字典-英文字典  2005-2009